Frelii Updates Strategic Roadmap to Target Five Key High Growth Market Segments
LEHI, Utah–(BUSINESS WIRE)–Frelii Inc. (OTCQX: FRLI), today provided a shareholder update on the
Company’s strategic roadmap detailing how it will further evolve its
proprietary DNA profiling artificial intelligence (AI) to meet the
growing demands of targeted market segments, including medical cannabis
use analysis, telehealth and precision medicine, life and health
insurance, consumer wellness and hospital systems.
Frelii continues to develop and grow its patented AI technology,
leveraged base code and large data sets gathered from public and private
partnerships. Frelii’s predictive capacity with its precision medicine
and health and wellness AI has increased from 84% to 98.5%. And the
flagship high-efficiency Genetic Sequencing and analysis using Frelii’s
proprietary technology has increased to greater than 99% and 99.999%
accuracy on whole genome and exome sequencing, respectively. Current
competitive solutions analyze approximately 400 thousand data points,
generating approximately 384 outcomes, such as diet suggestions or
identification of potential health risks. The Frelii AI technology has
dramatically increased the data points analyzed to over 60 million,
yielding more than 60 million outcomes.
Due to this continued expansion of its AI and market segment specific
UI, Frelii has been able to create negotiations with institutions and
organizations in each target market segment that will allow the Company
to maximize its business development, strategic growth and revenue for
the foreseeable future. The Company’s unique technology is particularly
attractive to these select segments because of the fundamentally
different approach Frelii takes using AI to interpret DNA testing
results. This will allow each roadmap market segment to have much
greater insight and decision making perspective than what is currently
available, creating greater competitive advantage for each partner and
alliance within their own respective markets.
“Current DNA analysis solutions that only take a few hundred thousand
data points into consideration run the risk of phenotypic misdiagnosis,”
said Ian Jenkins, CEO of Frelii. “We are providing a sea-change with our
profoundly more robust technological capabilities. We enable
visualization into epigenetic expression as clusters of millions of 3D
models. Through this, our AI derives meaning from the clusters with true
interconnected data. As such, we are opening the doors to far more
specific and accurate DNA analysis and far broader applications to a
number of market segments from precision medicine to life insurance and
beyond.”
Attention will still be given to the company’s consumer offerings;
however, the consistently expanding and growing capabilities make
Frelii’s offerings significant to expanded markets in the following ways:
-
Medical Cannabis Use Analysis. In geographies where medical cannabis
is legal, such as Canada, the application of Frelii’s AI can be used
to help medical professionals determine the best or most appropriate
plant genetics and dose to use with patients based on the patient’s
genetic information. The Frelii technology has the potential to
greatly impact how medical cannabis is used for medicinal purposes
making treatment safer, kinder and faster. -
Telemedicine and Precision Medicine. Because Frelii conducts
whole-genosequencing, its technology can be leveraged to advance
precision medicine when used for disease treatment and prevention by
taking into consideration an individual patient’s complete genome with
more than 60 million data points. Medical professionals and
researchers will be able to more accurately predict and provide
treatment strategies. -
Life and Health Insurance. Life insurance and other insurance
underwriting can be enhanced with the Company’s DNA-based health risk
capabilities. The Company believes that this application of its
technology may provide far more accurate underwriting than simple
blood tests and physical exams, which is the current method of
information gathering for life insurance providers. -
Consumer Wellness. Frelii has plans in the near future to offer
corporate wellness organizations the opportunity to enhance their
personalized wellness plans by ordering lab diagnostic kits for more
comprehensive blood testing and analysis. Additionally, Frelii will
continue to enable consumers to use their DNA to better understand
their unique nutrition and health needs and receive meal plans and
supplement recommendations specific to their needs. -
Hospital Systems. The Company’s technology and its application to
diagnostic, health risk identification and precision medicine could
improve health care and lower costs of health providers. Health
providers will use the Company’s technology to identify risks before
symptoms or complaints arise, when such health issues could be
addressed more efficiently and potentially more cost-effectively.
The company will provide further updates on strategic partnerships and
joint ventures within each target segment, as such agreements and
material contracts are executed.
About Frelii Inc.
Frelii Inc. is a medical technology company that uses genetic markers
and artificial intelligence to determine risk and lifestyle
modifications. Its technology analyzes the most comprehensive markers
(60,000,000 +) on the market to date. Frelii’s technology generates
accurate and profoundly valuable insight into DNA. It opens
opportunities never before realized in health care, precision medicine,
insurance, corporate wellness as well as personal health and risk
identification. For more information, please visit www.frelii.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement
This release contains certain “forward-looking statements” relating to
the business of the Company. All statements, other than statements of
historical fact included herein are “forward-looking statements”
including statements regarding: the continued growth of the e-commerce
segment and the ability of the Company to continue its expansion into
that segment; the ability of the Company to attract customers and
partners and generate revenues; the ability of the Company to
successfully execute its business plan; the business strategy, plans,
and objectives of the Company; and any other statements of
non-historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as “believes,”
“expects” or similar expressions and involve known and unknown risks and
uncertainties. Although the Company believes that the expectations
reflected in these forward-looking statements are reasonable, they do
involve assumptions, risks, and uncertainties, and these expectations
may prove to be incorrect. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date of
this news release. The Company’s actual results could differ materially
from those anticipated in these forward-looking statements as a result
of a variety of factors, including those discussed in the Company’s
periodic reports that are filed with the Securities and Exchange
Commission and available on its website (http://www.sec.gov).
All forward-looking statements attributable to the Company or persons
acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company
does not assume any duty to update these forward-looking statements.
Contacts
Tim Rush
Springboard5 PR
801-208-1100
tim.rush@springboard5.com
